UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

European journal of cancer (1990), 2019-09, Vol.118, p.10-34

2019

Volltextzugriff (PDF)

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

European journal of cancer (1990), 2019-07, Vol.116, p.207-215

2019

Volltextzugriff (PDF)

Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach

European journal of nuclear medicine and molecular imaging, 2020-09, Vol.47 (10), p.2313-2321

2020

Volltextzugriff (PDF)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

Targeted oncology, 2021-03, Vol.16 (2), p.197-205

2021

Volltextzugriff (PDF)

Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?

Neuroradiology, 2019-07, Vol.61 (7), p.775-782

2019

Volltextzugriff (PDF)

Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2021-04, Vol.70 (4), p.1089-1099

2021

Volltextzugriff (PDF)

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

European journal of cancer (1990), 2017-03, Vol.73, p.93-101

2017

Volltextzugriff (PDF)

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

The lancet oncology, 2018-05, Vol.19 (5), p.603-615

2018

Volltextzugriff (PDF)

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

The lancet oncology, 2018-10, Vol.19 (10), p.1315-1327

2018

Volltextzugriff (PDF)

Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from ‘Immunotherapy Bridge’

Immunotherapy, 2020-02, Vol.12 (3), p.167-174

2020

Volltextzugriff (PDF)

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

European journal of cancer (1990), 2017-09, Vol.83, p.247-257

2017

Volltextzugriff (PDF)

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

European journal of cancer (1990), 2020-05, Vol.130, p.126-138

2020

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1558-1568

2020

Volltextzugriff (PDF)

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

The lancet oncology, 2018-12, Vol.19 (12), p.e720-e725

2018

Volltextzugriff (PDF)

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera

Proteomics (Weinheim), 2016-05, Vol.16 (10), p.1570-1580

2016

Volltextzugriff (PDF)

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

European journal of cancer (1990), 2019-06, Vol.114, p.117-127

2019

Volltextzugriff (PDF)

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

European journal of cancer (1990), 2022-07, Vol.170, p.256-284

2022

Volltextzugriff (PDF)

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I–III patients

European journal of cancer (1990), 2021-01, Vol.143, p.11-18

2021

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

The Lancet (British edition), 2022-10, Vol.400 (10358), p.1117-1129

2022

Volltextzugriff (PDF)

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

European journal of cancer (1990), 2019-03, Vol.109, p.61-69

2019

Volltextzugriff (PDF)

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

European journal of cancer (1990), 2018-11, Vol.104, p.137-144

2018

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektioneBooks on EBSCOhost

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?

Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from ‘Immunotherapy Bridge’

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I–III patients

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Aktive Filter

Suchergebnisse filtern